Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. Karachaliou N, et al. Among authors: bria e. Sci Rep. 2023 Mar 3;13(1):3620. doi: 10.1038/s41598-023-30374-9. Sci Rep. 2023. PMID: 36869103 Free PMC article. No abstract available.
DNA repair by ERCC1 in non-small-cell lung cancer.
Cecere F, Bria E, Rosell R. Cecere F, et al. Among authors: bria e. N Engl J Med. 2006 Dec 14;355(24):2590-1; author reply 2591. doi: 10.1056/NEJMc062783. N Engl J Med. 2006. PMID: 17167144 No abstract available.
Sorafenib for lung cancer: is the "Battle" still open?
Bria E, Pilotto S, Tortora G. Bria E, et al. Expert Opin Investig Drugs. 2012 Oct;21(10):1445-8. doi: 10.1517/13543784.2012.707191. Epub 2012 Jul 16. Expert Opin Investig Drugs. 2012. PMID: 22799503
Clinical meta-analyses of targeted therapies in adenocarcinoma.
Bria E, Bonomi M, Pilotto S, Massari F, Novello S, Levra MG, Tortora G, Scagliotti G. Bria E, et al. Target Oncol. 2013 Mar;8(1):35-45. doi: 10.1007/s11523-013-0262-0. Epub 2013 Jan 25. Target Oncol. 2013. PMID: 23354875 Review.
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E. Pilotto S, et al. Among authors: bria e. Expert Opin Pharmacother. 2013 Apr;14(5):597-608. doi: 10.1517/14656566.2013.778828. Epub 2013 Mar 9. Expert Opin Pharmacother. 2013. PMID: 23472711 Review.
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. Vaccaro V, et al. Among authors: bria e. World J Gastroenterol. 2013 Jul 28;19(28):4511-9. doi: 10.3748/wjg.v19.i28.4511. World J Gastroenterol. 2013. PMID: 23901226 Free PMC article. Clinical Trial.
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
Vari S, Pilotto S, Maugeri-Saccà M, Ciuffreda L, Cesta Incani U, Falcone I, Del Curatolo A, Ceribelli A, Gelibter A, De Maria R, Tortora G, Cognetti F, Bria E, Milella M. Vari S, et al. Among authors: bria e. Expert Opin Drug Discov. 2013 Nov;8(11):1381-97. doi: 10.1517/17460441.2013.843523. Epub 2013 Oct 3. Expert Opin Drug Discov. 2013. PMID: 24088065 Review.
386 results